Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Tuesday after announcing updates for two of its HBV programs. The move translated to a loss of over

Read the full 283 word article

How to gain access

Continue reading with a
two-week free trial.